| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.0038 | 0.9 |